arrow_drop_up arrow_drop_down

Seagriculture 2019

8th International Seaweed Conference

"Seaweed Success Stories"

25-26 September 2019, Ostend, Belgium

Søren Kjærulff,
CEO Fermbiotics, DK

"Novel feed additives based on ensiled seaweeds and rapeseed”

WEDNESDAY

25-09-'19

10.40

Søren Kjærulff is the CEO of FermBiotics and also a co-founder of Lactobio. Formerly, he was Senior Director of Biopharma R&D at Novozymes AS, where he was responsible for leading biopharma research and development area in anti-infection and anti-inflammation. He has a Ph.D. in molecular biology from University of Copenhagen, Denmark and has published several peer-reviewed papers and several granted patents. Søren has been working with antimicrobial peptides (AMPs), albumin, transferrin, antibodies, hyaluronic acid and albumin half-life extension of peptides. Building a biopharmaceutical pipeline from early discovery to preclinical studies with several promising peptide drug candidates, e.g. Human Beta Defensin 2 for Inflammatory bowel diseases, Arenicin for Gram negative infections and Plectasin for Gram Positive infections published in Nature and Science journals.


Presentation

FermBiotics is a company developing natural fermented seaweed and plant products that support gut health.

Our product approach is innovative and fundamentally different from other approaches seen to date. We produce fermented plant and seaweed products as pet food supplements, food ingredients, dietary supplements and medical foods by combining prebiotics, probiotics and bioactive compounds.

FermBiotics is running two clinical studies in Inflammatory Bowel Diseases patients and in metabolic syndrome subjects with fermented seaweed and canola products in collaboration with Silkeborg Hospital and University of Copenhagen.

Book your conference

ticket now!